✦ LIBER ✦

9016 POSTER DISCUSSION Erlotinib Vs Chemotherapy (CT) in Advanced Non-Small-Cell Lung Cancer (NSCLC) Patients (p) With Epidermal Growth Factor Receptor (EGFR) Activating Mutations – the EURTAC Phase II Randomized Trial Interim Results

✍ Scribed by De Marinis, F.; Rosell, R.; Vergnenegre, A.; Massuti, B.; Felip, E.; Gervais, R.; Cardenal, F.; Garcia-Gomez, R.; Taron, M.; Paz-Ares, L.

Book ID: 122054033
Publisher: Elsevier Science
Year: 2011
Tongue: English
Weight: 43 KB
Volume: 47
Category: Article
ISSN: 0959-8049
DOI: 10.1016/S0959-8049(11)72328-0

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A prospective, phase II, open-label stud

A prospective, phase II, open-label study (JO22903) of first-line erlotinib in Japanese patients with epidermal growth factor receptor (EGFR) mutation-positive advanced non-small-cell lung cancer (NSCLC)

✍ Goto, Koichi; Nishio, Makoto; Yamamoto, Noboru; Chikamori, Kenichi; Hida, Toyoak 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 948 KB

92P ARCHER 1050: PHASE III RANDOMIZED ST

92P ARCHER 1050: PHASE III RANDOMIZED STUDY OF 1ST-LINE DACOMITINIB (D) VS GEFITINIB (G) FOR ADVANCED (ADV) NON-SMALL CELL LUNG CANCER (NSCLC) IN PATIENTS (PTS) WITH ACTIVATING EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) MUTATION(S)

✍ Mok, T.S.K.; Nakagawa, K.; Rosell, R.; Wu, Y.; Trygstad, C.; Capizzi, R.; DeBene 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 56 KB

55 Randomized phase II clinical trial of

55 Randomized phase II clinical trial of cetuximab in combination with cisplatin (C) and vinorelbine (V) or CV alone in patients with advanced epidermal growth factor receptor (EGFR)-expressing non-small-cell lung cancer (NSCLC)

✍ R. Rosell; R. Ramlau; A. Szczesna; C. Daniel; M. Bertrand; R. Garcia-Arroyo; K. 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 168 KB

O-245 Randomized phase II clinical trial

O-245 Randomized phase II clinical trial of cetuximab in combination with cisplatin and vinorelbine or cisplatin and vinorelbine alone in patients (pts) with advanced epidermal growth factor receptor (EGFR)-positive non-small-cell lung cancer (NSCLC)

✍ Rosell, Rafael; Constenla, Manuel; Kolb, Rainer; Pfeiffer, Wolfang; O'Bryne, Ken 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 178 KB

9017 POSTER DISCUSSION Initial Detection

9017 POSTER DISCUSSION Initial Detection of the Double Epidermal Growth Factor Receptor (EGFR) Mutation (L858R or Deletion in Exon 19 [del 19] Plus T790M) in Non-Small-Cell Lung Cancer (NSCLC) Patients (p) With Brain Metastases (mets) and the Influence of First-Line Chemotherapy on Outcome to Erlotinib

✍ Rolfo, C.; Moran, T.; Sanchez, J.; Molina-Vila, M.; Bertran-Alamilllo, J.; Camps 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 43 KB